Yale Study Identifies How Cancer Drug Inhibits DNA Repair in Cancer Cells
Yale Cancer Center researchers have found that a cancer drug thought to be of limited use possesses an unforeseen property. It is able to stop certain cancer cells from repairing their DNA in order to survive. The study suggests that combining this drug, cediranib, with other agents could potentially deliver a lethal blow in cancer that uses a specific process to create DNA repair cells.
Happy in Marriage? Genetics May Play a Role
People fall in love for many reasons — similar interests, physical attraction, and shared values among them. But if they marry and stay together, their long-term happiness may depend on their individual genes or those of their spouse, says a new study led by Yale School of Public Health researchers.
In the Developing Brain, Scientists Find Roots of Neuropsychiatric Diseases
The most comprehensive genomic analysis of the human brain ever undertaken has revealed new insights into the changes it undergoes through development, how it varies among individuals, and the roots of neuropsychiatric illnesses such as autism spectrum disorders and schizophrenia.
Broad genetic testing for advanced lung cancer may not improve survival
Testing for dozens of genetic mutations in tumors of patients with a common form of advanced lung cancer did not appear to improve survival compared to routine genetic testing, a study led by Yale Cancer Center (YCC) scientists has found.
Yale Cancer Researchers Suggest New Treatment for Rare Inherited Cancer
Studying two rare inherited cancer syndromes, Yale Cancer Center (YCC) scientists have found the cancers are driven by a breakdown in how cells repair their DNA. The discovery, published today in Nature Genetics, suggests a promising strategy for treatment with drugs recently approved for other forms of cancer.
Four Faculty Members Elected to the National Academy of Sciences
In recognition of their outstanding research achievements, four faculty members from the School of Medicine have been elected to the National Academy of Sciences (NAS). Akiko Iwasaki, PhD; Haifan Lin, PhD; David G. Schatz, PhD; and Günter Paul Wagner, PhD, were selected for one of the world’s highest honors that can be bestowed on a scientist.
Clinical trials take innovative approach
Since their arrivals at Yale within the past six years, Joseph Paul Eder, MD, and Patricia LoRusso, DO, have overseen a sharp increase in the number of clinical trials conducted by the Phase I Program at Yale Cancer Center. Bench investigators and the clinicians who design and conduct early-phase trials interact regularly, each sharing knowledge with the other that both strengthens the basic science and brings new discoveries to patients more quickly and effectively.
Scientist Joann Sweasy awarded Postdoctoral Mentoring Prize
Joann Sweasy treats the future of her postdocs with the same demanding attention and rigor she applies to experiments in her lab. For her strong advocacy for those working in her lab, Sweasy, the Ensign Professor of Therapeutic Radiology and professor of genetics, was awarded the Postdoctoral Mentoring Prize by the Provost’s Office at a ceremony at Harkness Auditorium Sept. 19.
Dr. Peter Glazer receives prestigious Outstanding Investigator Award for cancer research
The National Cancer Institute (NCI) has named Peter M. Glazer, M.D., Ph.D., as a recipient of its Outstanding Investigator Award (OIA). Glazer is the Robert E. Hunter Professor of Therapeutic Radiology, professor of genetics and chairman of the department of Therapeutic Radiology at Yale School of Medicine and Yale Cancer Center.
Yale Study: Minority Breast Cancer Patients Less Likely To Have Genetic Test
A genetic test that helps doctors determine how best to treat breast cancer—and whether chemotherapy is likely to help—is significantly more likely to be administered to white women than blacks or Hispanics, a Yale study has found.Source: Connecticut Health I-Team
Yale study reveals unequal access to breast cancer test
Gene expression profiling is an emerging technology for identifying genes whose activity may be helpful in assessing disease prognosis and guiding therapy. In recent years, gene expression profiling has been successfully used in breast cancer research, according to the federal government. Gene expression profiling substantially impacts treatment decision-making by determining which female breast cancer patients might—or might not—respond to particular treatment options. Although the tests are readily available, Yale Cancer Center researchers have found that white women with breast cancer are far more likely to receive a particular test than black or Hispanic women with the same diagnosis.Source: Life Science Daily
Yale scientists identify key defect in brain tumor cells
In a new study, Yale Cancer Center researchers identified a novel genetic defect that prevents brain tumor cells from repairing damaged DNA. They found that the defect is highly sensitive to an existing FDA-approved drug used to treat ovarian cancer — a discovery that challenges current practice for treatment of brain tumors and other cancers with the same genetic defect, said the scientists.
Yale scientists edit gene mutations in inherited form of anemia
A Yale-led research team used a new gene editing strategy to correct mutations that cause thalassemia, a form of anemia. Their gene editing technique provided corrections to the mutations and alleviated the disease in mice, the researchers said. The finding could lead to studies of a similar gene therapy to treat people with inherited blood disorders.
Yale Stem Cell Center will host two-day symposium to celebrate its 10th anniversary
Since it was founded in 2006, the Yale Stem Cell Center has supported the ground-breaking work of researchers and scientists working in basic stem cell research and translational science. On Thursday, Nov. 10, and Friday, Nov. 11, the center will hold a symposium in honor of its 10th anniversary.
Researchers find genes behind aggressive ovarian and endometrial cancers
In a major breakthrough for ovarian and uterine cancers, Yale researchers have defined the genetic landscape of rare, highly aggressive tumors called carcinosarcomas (CSs), pointing the way to possible new treatments. The findings are published in the Oct. 10 online early edition of Proceedings of the National Academy of Sciences.